Company Profiles

driven by the PitchBook Platform

Acer Therapeutics

Acer Therapeutics
2007 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Reverse Merger LATEST DEAL TYPE
$26M TOTAL AMOUNT RAISED
2 INVESTORS
Description

Developer of pharmaceutical therapeutics designed to treat serious rare diseases with critical unmet medical need. The company's pharmaceutical therapeutics offer treatment for serious ultra-rare diseases and severe genetic disorders, enabling healthcare companies to treat vascular ehlers-danlos syndrome and treatments of urea cycle disorders.

Website:
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Primary Office
222 Third Street
Suite 2240
Cambridge, MA 02142
United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Acer Therapeutics’s full profile, request a free trial.

Acer Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Reverse Merger 19-Sep-2017 $26M Completed Clinical Trials - General
4. Later Stage VC 19-Sep-2017 000.00 0000 Completed Clinical Trials - General
3. Later Stage VC (Series B) 05-May-2016 00.000 000.00 000.00 Completed Clinical Trials - General
2. Early Stage VC (Series A) 01-Apr-2015 $2.1M $2.1M $16.1M Completed Startup
1. Early Stage VC 01-Jan-2007 Completed Startup
To view this company’s complete deal history including valuation and funding request access »

Acer Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 000,000 00.000000 000 00.0 00.0 00 00.0 00.000
Series A 000,000 00.000000 000 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table request access »

Acer Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Bukwang Pharmaceutical Corporation Minority 000 0000 000000 0
TVM Capital Life Science Venture Capital Minority 000 0000 000000 0

You’re viewing 2 of 2 investors.

Acer Therapeutics Executive Team (6)

Name Title Board
Seat
Contact
Info
Christopher Schelling Co-Founder, Chief Executive Officer, President & Board Member
Pamela Williamson Acting Vice President, Regulatory Affairs
Benjamin Dewees Vice President, Regulatory Affairs and Manufacturing
Robert Steiner MD Chief Medical Officer
Harry Palmin Chief Financial Officer
You’re viewing 5 of 6 executives. Get the full list »

Acer Therapeutics Board Members (6)

Name Representing Role Since Contact
Info
Christopher Schelling Acer Therapeutics Co-Founder, Chief Executive Officer, President & Board Member 000 0000
Cynthia Lavoie Ph.D TVM Capital Life Science Board Member 000 0000
Hubert Birner Ph.D Self Board Member 000 0000
John Dunn JD Acer Therapeutics Board Member 000 0000
Luc Marengere Ph.D TVM Capital Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »